Table 2. Economic evaluation of inactivated virosomal influenza vaccination in children.
| Author | Perspective of the study | Risk status | Cost-benefit analysis | Cost-effectiveness analysis | ||
|---|---|---|---|---|---|---|
| Net present value | Benefit-cost ratio | |||||
| Navas et al.29 | Society | HR+LR | Cost-saving | 1.8 | ||
| Navas et al.29 | Provider | HR+LR | Not cost-saving | - | - Cost per episode of acute febrile respiratory process avoided | 5.0 euros |
| - Cost per pediatric visit avoided | 6.87 euros | |||||
| - Cost per episode of antibiotic consumption avoided | 25.18 euros | |||||
| - Cost per quality adjusted life year saved | 18.26 euros | |||||
| Salleras et al.30 | Family | LR | Cost-saving | 2.15 | ||